News
Merck to acquire Themis for SARS-CoV-2 vaccine
Merck announced on May 26 that it has entered an agreement to acquire privately held Themis, a company that is developing a vaccine candidate...
Drug Research
Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced that the companies have...
Clinical Trials
Glenmark to Combine Two Anti-Viral Drugs; Start Trials on Indian COVID-19 Patients
Glenmark Pharmaceuticals announced on Tuesday that it will commence another new Phase 3 clinical trial on a combination of two anti-viral drugs Favipiravir and...
Clinical Trials
AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials
AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalised cancer monitoring to detect minimal residual disease (MRD)...
Press Releases
Takara Bio Selects AGC Biologics as Manufacturer of Plasmid DNA Intermediate for a Vaccine Against COVID-19
AGC Biologics, a global Contract Development and Manufacturing Organization (CDMO) for Biopharmaceuticals, has announced its partnership with Takara Bio. The companies will partner in...
Press Releases
Mondi to produce melt blown nonwoven fabric and one million surgical face masks a day with new production lines in Germany
Mondi, global leader in packaging and paper, is set to build new production lines in its plant in Gronau, Germany, to produce melt blown...
Articles
Rethinking Travel as Part of a Good Patient-Centric Clinical Trial
The landscape for clinical trials has seemingly been turned upside down with the onset of the COVID-19 pandemic. However, there is one factor that...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read